Close Menu

TriLink

This story has been updated from a previously posted version.
Enzo Diagnostics has been awarded US Patent No. 8,133,989, "Nucleic acid primer/construct compositions."

TriLink Biotechnologies said this week that it has entered into a distribution agreement with Sigma-Aldrich to sell TriLink's CleanAmp dNTPs globally.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – TriLink BioTechnologies today said that Sigma-Aldrich will sell and distribute the firm's CleanAmp dNTPs globally.

TriLink Biotechnologies said today that it has entered into a distribution agreement with Australia's Astral Scientific.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – TriLink BioTechnologies today announced a distribution deal covering Australia with Astral Scientific for its nucleic acid products.

A US district court has dismissed a lawsuit filed earlier this year against more than a dozen life science companies alleging that they falsely marked certain nucleic acid detection, amplification, and cloning technologies as being patented after the relevant patents expired.

Under the agreement, Lucigen will use the CleanAmp dNTPs in its Taq98 Hot Start 2X MasterMix.

By replacing the standard dNTPs in a PCR assay with CleanAmp dNTP, a Hot Start reaction can be achieved, resulting in a cost-effective method to "vastly reduce mis-priming."

The Scandinavian biocenter will distribute TriLink's CleanAmp Products.

TriLink Biotechnologies has entered into a distribution agreement with TATAA Biocenter to sell TriLink's CleanAmp products.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.